A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
25/01/2022at 10:20

New CCO at crisis-hit Lundbeck: "2022 will be a growth year for Lundbeck in all regions"

Jacob Tolstrup will be responsible for renewing sales growth at Lundbeck, having made his way through the ranks.
Jacob Tolstrup, executive vice president and chief commercial officer of commercial operations at Lundbeck | Photo: PR / Lundbeck
Finans
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen

The pipeline has failed, sales of migraine drug Vypeti, which cost billions to acquire, have failed, and so, it seems, has the firm’s ability to make money. Still, the pharmaceutical company’s new CCO, Jacob Tolstrup, is optimistic on Lundbeck’s behalf.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Lundbeck / PR

    Lundbeck's migraine drug approved in EU

    For subscribers

  • Johan Luthman, head of R&D at Lundbeck | Photo: PR / Lundbeck

    Lundbeck receives grant from Michael J. Fox Foundation in hunt for Parkinson's test

    For subscribers

  • Johan Luthman, head of Research and Development at Lundbeck | Photo: PR / Lundbeck

    Lundbeck has great expectations for new antibody: "This could be the new generation of migraine drugs"

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

GN’s proposed board member, Klaus Holse, runs in the same board circles as the CEO of William Demant Invest – but GN says the pick is unrelated to ”any conceivable or inconceivable acquisition.”

For subscribers

Foto: Coloplast / Pr
Medtech

Coloplast is the world's most sustainable medtech firm in new analysis

Among 87 of the largest, publicly listed medtech companies, Coloplast has been deemed the very best on sustainability, according to a new international ranking. 

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

FDA approves Novo Nordisk's Rybelsus as first-line treatment option

Rybelsus, the tablet formulation of semaglutide, has now been approved in the US as a first-line treatment option for adults with type 2 diabetes.

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Head of Regulatory Affairs Danmark

  • Experienced Patent Counsel

  • Head of International Sales

  • Application Manager

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Principal Laboratory Technologist

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Senior Regulatory Affairs Professional

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Lead Data Architect

  • Clinical Operational Associate

  • Commercial Director

See all jobs

Jobs

  • Head of Regulatory Affairs Danmark

  • Experienced Patent Counsel

  • Head of International Sales

  • Application Manager

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Principal Laboratory Technologist

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Senior Regulatory Affairs Professional

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Lead Data Architect

  • Clinical Operational Associate

  • Commercial Director

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge